Breast Cancer Research and Treatment

, Volume 1, Issue 2, pp 125–130 | Cite as

Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer

A preliminary report of clinical and experimental studies
  • Masaru Izuo
  • Yuichi Iino
  • Keiichi Endo
US-Japan Conference on Chemoendocrine Therapy


Medroxyprogesterone acetate (MAP) in the treatment of advanced breast cancer has been regarded as a minor agent according to the previous reports when used at low doses (<500 mg/day). High doses of more than 500 mg which have come into use since 1973 give a response rate of over 40%, but sometimes cause gluteal abcess or induration because of daily intramuscular injections.

In order to administer easily and to avoid the side effect, we have attempted to use oral administration in a daily dose of 1200mg (400 mg × 3). Of those 20 patients treated with oral high-dose MAP, 1 showed complete response, 6 showed partial response, 7 no change, and 6 progressive disease. As for site of lesion, 4 out of 6 (67%) in skin and 4 out of 16 (25%) in bone responded. Neither severe side effects nor abnormal laboratory data were seen.

Then, we examined the blood levels of MAP in vivo by RIA in 9 patients. The blood level of MAP reached 39–250 ng/ml in 3 days and was maintained at least over 50 ng/ml for 1 or 2 months of continuous administration. Subsequently, we examined the effects of MAP on binding to ER in vitro. The inhibition of binding of estradiol-17β to ER was about 60% at 10−5 M MAP. The blood level of 50 ng/ml in vivo corresponds to about 1.3 × 10−5 M.


medroxyprogesterone acetate (MAP) oral high-dose hormone therapy breast cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ganzina F: High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65: 563–585, 1979.Google Scholar
  2. 2.
    Pannuti F, Martoni A, Pollutri E, Camera P, Lenaz GR: Medroxyprogesterone acetate (MPA): Effect of massive doses in advanced breast cancer. IRCS Med Sci 2: 1065, 1974Google Scholar
  3. 3.
    Amadori D, Ravaioli A, Barbanti F: L'impiego del Medrossiprogesterone acetato ad alti dosaggi nella terapia palliativa del carcinoma mammario in fase avanzata. Min Med 67: 1–14, 1976Google Scholar
  4. 4.
    Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P: A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62: 499–504, 1978PubMedGoogle Scholar
  5. 5.
    Robustelli Della Cuna G, Calciati A, Bernardo Strada MR, Bumma C, Campio L: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose response evaluation. Tumori 64: 143–150, 1978PubMedGoogle Scholar
  6. 6.
    De Lena M, Brambilla C, Valagussa P, Bonadonna G: High dose medroxyprogesterone acetate (MPA) in metastatic breast cancer previously treated with chemotherapy. Cancer Chemother Pharmacol 2: 175–180, 1979PubMedGoogle Scholar
  7. 7.
    Mattsson W: High dose medroxyprogesterone acetate treatment in advanced mammary carcinoma. A phase II investigation. Acta Radiol Oncol 17: 387–400, 1978Google Scholar
  8. 8.
    Shrimanker K, Saxena BN, Fortherby K: A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem 9: 359–363, 1978PubMedGoogle Scholar
  9. 9.
    Iino Y, Izuo M, Takikawa H: A study of estrogen and progesterone receptors in human breast cancer by sucrose gradient centrifugation. Jpn J Clin Oncol 10: 49–60, 1980Google Scholar
  10. 10.
    Pannuti F, Di Marco AR, Martoni A, Fruet F, Strocchi E, Burroni P, Rossi AP, Cricca A: Medroxyprogesterone acetate in treatment of metastatic breast cancer: Seven years of experience,In S Iacobelli and A Di Marco (eds): Role of Medroxyprogesterone in Endocrine-related Tumors. Raven Press, New York, 1980, pp 73–92Google Scholar
  11. 11.
    Cornette JC, Kirton KT, Duncan GW: Measurement of Medroxyprogesterone acetate (Provera) by radioimmunoassay. J Clin Endocrinol Metab 33: 459–466, 1971PubMedGoogle Scholar
  12. 12.
    Jeppsson S, Johansson EDB: Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-Provera to women. Contraception 14: 461–469, 1976PubMedGoogle Scholar
  13. 13.
    Ortiz A, Hiroi M, Stanczyk FZ, Goebelsmann U, Mishell DR jr: Serum medroxyprogesterone accetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. J Clin Endocrinol Metab 44: 32–38, 1977PubMedGoogle Scholar
  14. 14.
    Salimtschik M, Mouridsen HT, Loeber J, Johansson E: Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Cancer Chemother Pharmacol 4: 267–269, 1980PubMedGoogle Scholar
  15. 15.
    McGuire WL, Horwitz KB, Pearson OH, Segaloff A: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39: 2934–2947, 1977PubMedGoogle Scholar
  16. 16.
    Tanaka M, Abe K, Ohnami S, Adachi I, Yamaguchi K, Minakawa S: Tamoxifen in advanced breast cancer: Response rate, effect on pituitary hormone reserve and binding affinity to estrogen receptor. Jpn J Clin Oncol 8: 141–148, 1978Google Scholar
  17. 17.
    Miyake T, Hori T, Suzuki T: Epithioandrostanol (10275-S), an estrogen antagonist. Endocrinol Jpn 20: 157–165, 1973PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1981

Authors and Affiliations

  • Masaru Izuo
    • 1
  • Yuichi Iino
    • 1
  • Keiichi Endo
    • 1
  1. 1.Department of SurgeryGunma University School of MedicineMaebashiJapan

Personalised recommendations